Kathryn Sowerwine
Internal Medicine · Washington, DCNPI 1477712867
Payments from drug & device makers
Across 1,468 payments — averaging $566.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$361K
- Regeneron Healthcare Solutions, Inc.$339K
- AbbVie$37K
- Arcutis Biotherapeutics, Inc.$22K
- Pfizer$13K
- Novartis$13K
- plus $46K from 25 others
Across 1 payment — averaging $1200.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$1K
What the payments were for
- Consulting fees$100,17712%
- Speaking & faculty fees$620,28875%
- Travel & lodging$83,40810%
- Food & beverage$27,1763%
- Education$1420%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 363 | $361,258 |
| Regeneron Healthcare Solutions, Inc. | 492 | $338,794 |
| AbbVie | 135 | $37,088 |
| Arcutis Biotherapeutics, Inc. | 37 | $22,474 |
| Pfizer | 87 | $13,333 |
| Novartis | 33 | $12,680 |
| Dermavant Sciences, Inc. | 20 | $11,759 |
| Lilly USA, LLC | 63 | $8,310 |
| Organon | 11 | $7,048 |
| Kowa Pharmaceuticals America, Inc. | 7 | $6,975 |
| Regeneron | 8 | $6,102 |
| UCB, Inc. | 22 | $1,690 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 45 | $790 |
| Incyte Corporation | 22 | $491 |
| LEO Pharma Inc. | 27 | $475 |
| E.r. Squibb & Sons, L.L.C. | 20 | $464 |
| Johnson & Johnson | 17 | $360 |
| Sun Pharmaceutical Industries Inc. | 17 | $296 |
| Galderma Laboratories, L.p. | 11 | $196 |
| Boehringer Ingelheim | 4 | $94 |
| VYNE Pharmaceuticals Inc. | 6 | $88 |
| Mayne Pharma Commercial LLC | 5 | $87 |
| Bristol Myers Squibb | 3 | $81 |
| EPI Health, LLC | 3 | $55 |
| Almirall LLC | 3 | $50 |
| Sanofi-aventis U.S. LLC | 2 | $46 |
| Genentech USA, Inc. | 1 | $30 |
| Aclaris Therapeutics, Inc. | 1 | $25 |
| Amgen | 1 | $19 |
| Journey Medical Corporation | 1 | $16 |
| Botanix SB Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$831,191 in reported general payments places this provider in the 95th percentile of 645 internal medicine providers in District of Columbia.
See all internal medicine providers in District of Columbia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Clobetasol Propionate | 21 | $861 |
| Doxycycline Monohydrate | 19 | $379 |
| Ketoconazole | 17 | $182 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Washington
- Federico AschWashington$4.6M
- Geoffrey GibneyWashington$2.3M
- Nnemdi Kamanu EliasWashington$939K
- Andrea SingerWashington$930K
- Douglas WardWashington$454K
- Ida BergstromWashington$295K
- Miriam CameronWashington$290K
- Bruce RashbaumWashington$265K
- Kevin GriffithsWashington$180K
- Maryam Sarraf YazdyWashington$165K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.